Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 19 of 19 for “"CYP2C19"”.
-
Economic Evaluation of a Point of Care Pharmacogenetic Test (CYP2C19) from an Ontario Perspective
… depends on the functional capacity of their CYP2C19*2 allele. Patients with a fully functional allele could be treated with clopidogrel while prasugrel or ticagrelor could be prescribed to patients with a loss of function allele. Pharmacogenetic (PGx) testing could optimize pharmacotherapy …
-
Advancing Precision Medicine in Psychiatry: Genetic Insights into Antidepressant Treatment Outcomes
… particularly in pharmacokinetic genes such as CYP2C19 (drug metabolizing enzyme) and ABCB1 (encoding the drug-efflux transporter P-glycoprotein), and broader polygenic liability may partly explain this variability. Recent advances in psychiatric genomics have enabled the use of polygenic risk …
-
Meta-analysis of the population and phenotypic expression of CYP2C9/2C19 polymorphism on drug metabolism in different ethnicities
… respectively; the pooled prevalence of CYP2C19*1 is about 86%, 57%, 58% and 85% in these ethnic populations respectively. However, the studies of association between CYP2C9/2C19 polymorphism and phenytoin metabolism failed to achieve any qualitative or quantitative conclusion. Therefore, …
-
Migreenin estolääkkeen amitriptyliinin metaboloitumisen geneettiset erot Itä- ja Länsi-Suomessa
… määritettiin kolmen CYP-entsyymin (CYP2C9, CYP2C19, CYP2D6) fenotyyppien esiintyvyys itä- ja länsisuomalaisissa. Tutkimustulosten mukaan eroavaisuudet fenotyyppien esiintyvyydessä itä- ja länsisuomalaisten välillä olivat maltillisia. Amitriptyliinin metaboliassa erityisen oleellisen CYP2C19 …
-
Πρωτόκολλο μελέτης προσδιορισμού της αντιδραστικότητας των αιμοπεταλίων με τη συσκευή μέτρησης VerifyNow σε ασθενείς υπό αιμοκάθαρση : σύγκριση της διπλής δόσης κλοπιδογρέλης (150mg) έναντι πρασουγρέλης (10mg)
… units) ≥235. Επίσης μελετήθηκε η παρουσία του CYP2C19*2 loss-of-function αλληλίου ως πιθανού παράγοντα που σχετίζεται με την αντιδραστικότητα των αιμοπεταλίων. Αποτελέσματα: Το πρωτεύον καταληκτικό σημείο της αντιδραστικότητας των αιμοπεταλίων ήταν χαμηλότερο στους ασθενείς που έλαβαν …
-
Pharmacokinetics of Bupropion and its Pharmacologically Active Metabolites in Pregnancy
… majorly to pharmacological efficacy of the drug. CYP2C19 enzyme is involved in hydroxylation of bupropion, as well as TB and EB. Pregnancy-associated changes in maternal physiology may alter the pharmacokinetics of bupropion and thus influence the efficacy of bupropion in promoting cessation in …
-
Erradicación de helicobacter pylori : una propuesta desde la farmacogenética y la epigenética en una población de Bogotá
… la influencia de los polimorfismos genéticos de CYP2C19 en la erradicación de H. pylori y de manera prospectiva en ausencia de resistencia bacteriana, determinar si al erradicar la infección se elimina o disminuye la metilación de los genes CDH1 y CDKN2A, los cuales se consideran cambios …
-
Metabolism of nonylphenol by human P450-recombinant yeast and assessment of the xeno-hormone potency of different isomers and their chlorinated derivates
… cell culture, able to express the human proteins CYP2C19 and CYP2B6 (cytochromes P450) for model degradation studies. Two different systems were created: System 1: the YR and the cytochrome P450 monooxyigenase were inserted in one plasmid under the control of a strong galactose-inducible promoter. …
-
Genotype- versus phenotype-directed personalization of antiplatelet treatment in Koreans with coronary artery disease undergoing coronary stenting
… treatment. All patients were screened for the CYP2C19 *2, *3, or *17 alleles by using Verigene CLO assay (Nanosphere, Northbrook, IL, USA). On-treatment platelet reactivity was measured using the VerifyNow P2Y12 assay (Accumetrics, San Diego, CA, USA). 21 CYP2C19 *2 or *3 carriers (65.6%) or 11 …
-
The interactions of Propafenone and its enantiomers with the major human forms of cytochrome P450 in terms of inhibition and metabolic rates
… P450 isoforms (CYP2D6, CYP1A2, CYP3A4 and CYP2C19) to determine any stereospecific differences which may exist. This was conducted by measuring the in vitro metabolism of propafenone (racemate and enatiomers) and by developing CYP inhibition screens which could prove to be useful in …
-
Treatments and outcomes in bipolar disorder
… Finally, in study V, we studied the impact of CYP2C19 polymorphisms on antidepressant treatment patterns as well as the risk for treatment emergent mania using a large sample of patients with bipolar disorder. The mainly negative results suggest that information on CYP2C19 genotype has limited …
-
Metabolismus von 14 C-Methoxychlor in humanen P450- transgenen und nicht-transgenen Pflanzenzellkulturen zur Produktion endokrin-wirksamer Metaboliten sowie deren Untersuchung auf östrogene Wirkung
… separately with cDNA of human Cyp3a4 (3DcA4) and Cyp2c19 (2DcC19) via Agrobacterium tumefaciens. Expression of the P450 genes was succesfully proven by PCR and detection of the corresponding mRNA. The growth of all new cell cultures was monitored by fresh weight, dry weight, conductivity and pH of …
-
In vitro metabolism studies to inform physiologically-based pharmacokinetic modelling of mefloquine, ritonavir and proguanil
… by a number of enzymes, namely CYP1A2, CYP2D6, CYP2C19 and CYP3A. This confirms reported data for CYP2C19 and CYP3A, and provides new data for CYP1A2 and CYP2D6. Lastly, ritonavir was found to be metabolized by CYP2D6 and CYP3A. These determined fm,CYPs were then used, along with available data …
-
Nuevos factores genéticos asociados a la predisposición de crisis en Porfiria Aguda Intermitente.
… ALAS1 y en los genes de los citocromos CYP2C9, CYP2C19, CYP2D6, CYP3A4 y CYP3A5 que actúen como factores de susceptibilidad para la manifestación de crisis agudas en los portadores de PAI. Material y métodos: Se realizó un estudio retrospectivo de la ocurrencia de crisis (PAI manifiesta) en 50 …
-
Human Genetics, Psychotropic Drugs, and Acts of Violence
… 4 variant alleles for CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 or CYP3A4.</p> <p>• Three or more prescription medications, especially when an antidepressant or other psychoactive medication is prescribed.</p> <p>• An intermediate phenotype for CYP3A4.</p> <p>• Fluctuating levels of psychoactive …
-
Studies on pro-oxidant cytochrome P450 enzymes as drug discovery tools and the discovery that they also have a dual function as antioxidants
… libraries of chemical compounds. (ii) CYP1A2, CYP2C19, CYP2D6, CYP2C9 and CYP3A4 are major liver enzymes that are widely used to study drug metabolism (i.e. metabolism of medicines). These particular CYPs metabolise medicines into more polar substances through such reactions as hydroxylation …
-
Engineered microtissue platforms for modeling human pathophysiology and drug metabolism
… reflected donor hetereogeneity in CYP2D6 and CYP2C19 enzyme activity levels, and performed xenobiotic detoxification on circulating drugs, establishing the ability to incorporate hepatic functions in 'human-on-a-chip' devices. Collectively, these three applications of cell-laden microtissues …
-
Quantitative assessment of the pharmacotherapy of biopolar disorder and schizophrenia
… (CYP2D6) and the S-mephenytoin hydroxylase (CYP2C19) are polymorphic P450 enzymes with particular importance in psychopharmacotherapy. The enzymes are responsible for the metabolism of many commonly used antipsychotic and antidepressant drugs. The incidence of poor metabolisers of …